Overview Of Hot Melt Extrusion And Its Pharmaceutical Applications

More than 40% of new chemical entities in development face aqueous solubility challenges that can limit commercial viability, regardless of pharmacological promise. Hot melt extrusion offers a solvent-free, continuous processing path that addresses this problem while also enabling abuse deterrence, modified release, taste masking, implant preparation, and continuous granulation within a single technology platform.

Successfully applying HME requires careful characterization of thermal properties, drug-polymer miscibility, and melt rheology before processing parameters can be reliably set. Scaling from bench to commercial production introduces additional complexity, with specific mechanical energy, residence time distribution, and geometric similarity between extruders all playing a role in whether small-scale results translate.

This white paper covers the formulation and processing variables that govern HME outcomes and the scale-up strategies available when moving toward commercial manufacture. Explore the full paper to see how these considerations apply across the range of pharmaceutical applications HME supports.